# US 2001/0044457 A1 · Cancer Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044457 A1
- Document ID: US20010044457A1
- Status: Published application
- Kind: A1
- Application number: 09/758,803
- Filed: 2001-01-11
- Published: 2001-11-22
- Earliest claimed: 2000-04-25
- Inventors: James Berger Camden
- Web page: https://patentgrep.com/patent/US20010044457A1

## CPC

- C07D 233/88: Nitrogen atoms, e.g. allantoin
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing a imidazole-1,2-diamine derivative. The imidazole-1,2-diamine derivative is selected from the group consisting of: 1 wherein Y and X are independently selected from the group consisting of hydrogen, halogen, e.g., chloro, fluoro, nitro, methyl, ethyl, oxychloro or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 5; R1 and R2 are independently selected form the group consisting of hydrogen and the pharmaceutically acceptable salts and prodrugs thereof.

## Claims

### Claim 1

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a imidazole-1,2-diamine compound selected from the group consisting of:
8
wherein Y and X are independently selected from the group consisting of hydrogen, halogen, nitro, methyl, ethyl, oxychloro or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 5; R1 and R2 are independently selected from the group consisting of hydrogen and the pharmaceutically acceptable salts and prodrugs thereof.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said cancer is prostate cancer.

### Claim 3 (depends on 1)

A method according to claim 1 wherein said cancer is melanoma.

### Claim 4 (depends on 1)

A method according to claim 1 wherein said cancer is leukemia.

### Claim 5 (depends on 1)

A method according to claim 1 wherein said cancer is pancreatic cancer.

### Claim 6 (depends on 1)

A method according to claim 1 wherein said cancer is neuroblastoma.

### Claim 7 (depends on 1)

A method according to claim 1 wherein said cancer is cervical cancer.

### Claim 8 (depends on 1)

A method according to claim 1 wherein said cancer is ovarian cancer.

### Claim 9 (depends on 1)

A method according to claim 1 wherein said cancer is stomach cancer.

### Claim 10 (depends on 1)

A method according to claim 1 wherein said cancer is a sarcoma.

### Claim 11 (depends on 1)

A method according to claim 1 wherein said cancer is a lymphoma.

### Claim 12 (depends on 1)

A method according to claim 1 wherein said cancer is breast cancer.

### Claim 13 (depends on 1)

A method according to claim 1 wherein said cancer is lung cancer.

### Claim 14 (depends on 1)

A method according to claim 1 wherein said cancer is colon cancer.

### Claim 15 (depends on 1)

A method according to claim 1 wherein said imidazole-1,2-diamine compound is selected from the group consisting of:
9
and pharmaceutically acceptable acid salts and prodrugs thereof.

### Claim 16

A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising a imidazole-1,2-diamine compound selected from the group consisting of:
10
wherein Y and X are independently selected from the group consisting of hydrogen, halogen, nitro, methyl, ethyl, oxychloro or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 5; R1 and R2 are independently selected form the group consisting of hydrogen and the pharmaceutically acceptable salts and prodrugs thereof.

### Claim 17 (depends on 16)

A pharmaceutical composition of claim 16 further comprising a pharmaceutical carrier.

### Claim 18 (depends on 17)

A pharmaceutical composition according to claim 17 comprising a pharmaceutical carrier and a safe and effective amount of a potentiator.

### Claim 19 (depends on 18)

A pharmaceutical composition according to claim 18, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2′-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.

### Claim 20 (depends on 16)

A pharmaceutical composition according to claim 16 further comprising a safe and effective amount of a chemotherapeutic agent.

### Claim 21 (depends on 20)

A pharmaceutical composition according to claim 20 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, hormonal agent, asparaginase and hydroxyurea.

### Claim 22 (depends on 20)

A pharmaceutical composition according to claim 20 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole and Plicamycin.

### Claim 23 (depends on 20)

A pharmaceutical composition according to claim 20 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Floxuridine, Mercaptopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine.

### Claim 24 (depends on 20)

A pharmaceutical composition according to claim 20 further comprising a safe and effective amount of a potentiator.

### Claim 25 (depends on 24)

A pharmaceutical composition according to claim 24, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl]acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2′-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.

### Claim 26

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a combination therapy comprising a imidazole-1,2-diamine compound selected from the group consisting of:
11
wherein Y and X are independently selected from the group consisting of hydrogen, halogen, nitro, methyl, ethyl, oxychloro or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 5; R1 and R2 are independently selected from the group consisting of hydrogen and the pharmaceutically acceptable salts and prodrugs thereof, and a safe and effective amount of a chemotherapeutic agent.

### Claim 27 (depends on 26)

A method according to claim 26 wherein said cancer is prostate cancer.

### Claim 28 (depends on 26)

A method according to claim 26 wherein said cancer is leukemia.

### Claim 29 (depends on 26)

A method according to claim 26 wherein said cancer is pancreatic cancer.

### Claim 30 (depends on 26)

A method according to claim 26 wherein said cancer is breast cancer.

### Claim 31 (depends on 26)

A method according to claim 26 wherein said cancer is lung cancer.

### Claim 32 (depends on 26)

A method according to claim 26 wherein said cancer is colon cancer.

### Claim 33 (depends on 26)

A method according to claim 26 wherein said imidazole-1,2-diamine compound is selected from the group consisting of:
12
and pharmaceutically acceptable acid salts and prodrugs thereof.

### Claim 34 (depends on 32)

A method according to claim 32 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, hormonal agent, asparaginase and hydroxyurea.

### Claim 35 (depends on 32)

A method according to claim 32 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole and Plicamycin.

### Claim 36 (depends on 32)

A method according to claim 32 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Floxuridine, Mercaptopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine.

### Claim 37 (depends on 32)

A method according to claim 32 further comprising a safe and effective amount of a potentiator.

### Claim 38 (depends on 37)

A method according to claim 37, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N′-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl]acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2′-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.

### Claim 39

A liposome composition comprising a imidazole-1,2-diamine compound selected from the group consisting of:
13
wherein Y and X are independently selected from the group consisting of hydrogen, halogen, nitro, methyl, ethyl, oxychloro or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 5; R1 and R2 are independently selected form the group consisting of hydrogen and the pharmaceutically acceptable salts and prodrugs thereof.

### Claim 40 (depends on 39)

A liposome composition according to claim 39 selected from the group of consisting of unilamallar vesicle and multilamaller vesicles.

### Claim 41 (depends on 40)

A lipsome composition according to claim 40 formed from phospholipids cholesterol, stearylamine or phosphahidyl choline.

### Claim 42

A pharmaceutical composition comprising the hydrochloride salt of a imidazole-1,2-diamine compound having the structure:
14
